APO Research
Talk to an analyst

APO RESEARCH · REPORT

Glucagon-like Peptide-2 (GLP-2) Agonist

Compare research editions
View pricing & licenses

Selected research

Industry Research

Glucagon-like Peptide-2 (GLP-2) Agonist Industry Research Report 2026

2 January 2026106 pages

Choose your research edition.

Industry ResearchGlucagon-like Peptide-2 (GLP-2) Agonist Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Industry Growth and Trends Forecast to 203270 pages · $3,450 USDMarket StructureGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Glucagon-like Peptide-2 (GLP-2) Agonist market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Glucagon-like Peptide-2 (GLP-2) Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Glucagon-like Peptide-2 (GLP-2) Agonist is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Glucagon-like Peptide-2 (GLP-2) Agonist is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist include Takeda Pharmaceuticals. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Glucagon-like Peptide-2 (GLP-2) Agonist market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Glucagon-like Peptide-2 (GLP-2) Agonist Market by Company

Takeda Pharmaceuticals

Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Type

Gattex

Revestive

Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Application

Hospital

Pharmacy

Other

Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucagon-like Peptide-2 (GLP-2) Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Glucagon-like Peptide-2 (GLP-2) Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucagon-like Peptide-2 (GLP-2) Agonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Glucagon-like Peptide-2 (GLP-2) Agonist manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Glucagon-like Peptide-2 (GLP-2) Agonist by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Glucagon-like Peptide-2 (GLP-2) Agonist in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Glucagon-like Peptide-2 (GLP-2) Agonist Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Manufacturers (2021-2026) Table 8. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue of Manufacturers (2021-2026) Table 9. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Glucagon-like Peptide-2 (GLP-2) Agonist Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Glucagon-like Peptide-2 (GLP-2) Agonist Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Product Type & Application Table 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Glucagon-like Peptide-2 (GLP-2) Agonist by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Takeda Pharmaceuticals Company Information Table 19. Takeda Pharmaceuticals Business Overview Table 20. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Portfolio Table 22. Takeda Pharmaceuticals Recent Developments Table 23. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 24. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2021-2026) & (K Units) Table 25. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2021-2026) Table 26. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2027-2032) & (K Units) Table 27. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2027-2032) Table 28. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2021-2026) & (US$ Million) Table 29. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2021-2026) Table 30. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2027-2032) & (US$ Million) Table 31. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2027-2032) Table 32. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 33. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 34. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2027-2032) & (K Units) Table 35. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2021-2026) & (US$ Million) Table 36. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2027-2032) & (US$ Million) Table 37. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 39. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2027-2032) & (K Units) Table 40. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2021-2026) & (US$ Million) Table 41. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2027-2032) & (US$ Million) Table 42. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 44. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2027-2032) & (K Units) Table 45. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2021-2026) & (US$ Million) Table 46. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2027-2032) & (US$ Million) Table 47. South America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 48. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 49. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2027-2032) & (K Units) Table 50. South America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2021-2026) & (US$ Million) Table 51. South America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2027-2032) & (US$ Million) Table 52. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 54. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2027-2032) & (K Units) Table 55. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2021-2026) & (US$ Million) Table 56. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2027-2032) & (US$ Million) Table 57. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (K Units) Table 58. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2027-2032) & (K Units) Table 59. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2021-2026) Table 60. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2027-2032) Table 61. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021-2026) & (US$ Million) Table 62. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2027-2032) & (US$ Million) Table 63. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2021-2026) Table 64. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2027-2032) Table 65. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2021-2026) & (US$/Unit) Table 66. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2027-2032) & (US$/Unit) Table 67. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (K Units) Table 68. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2027-2032) & (K Units) Table 69. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2021-2026) Table 70. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2027-2032) Table 71. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021-2026) & (US$ Million) Table 72. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2027-2032) & (US$ Million) Table 73. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2021-2026) Table 74. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2027-2032) Table 75. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2021-2026) & (US$/Unit) Table 76. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2027-2032) & (US$/Unit) Table 77. Key Raw Materials Table 78. Raw Materials Key Suppliers Table 79. Glucagon-like Peptide-2 (GLP-2) Agonist Distributors List Table 80. Glucagon-like Peptide-2 (GLP-2) Agonist Customers List Table 81. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Trends Table 82. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Drivers Table 83. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Restraints Table 84. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Glucagon-like Peptide-2 (GLP-2) Agonist Product Image Figure 5. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size (2021-2032) & (US$ Million) Figure 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (2021-2032) & (K Units) Figure 8. Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price (US$/Unit) & (2021-2032) Figure 9. Gattex Product Image Figure 10. Revestive Product Image Figure 11. Hospital Product Image Figure 12. Pharmacy Product Image Figure 13. Other Product Image Figure 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Glucagon-like Peptide-2 (GLP-2) Agonist Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region in 2025 Figure 20. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region in 2025 Figure 21. North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country in 2025 Figure 22. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2021-2032) Figure 23. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2021-2032) Figure 24. United States Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country in 2025 Figure 27. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2021-2032) Figure 28. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2021-2032) Figure 29. Germany Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. France Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. U.K. Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Italy Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Netherlands Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country in 2025 Figure 35. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2021-2032) Figure 36. Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2021-2032) Figure 37. China Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Japan Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. India Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Australia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. China Taiwan Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country in 2025 Figure 46. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2021-2032) Figure 47. South America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2021-2032) Figure 48. Mexico Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Brazil Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Argentina Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country in 2025 Figure 52. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2021-2032) Figure 53. Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2021-2032) Figure 54. Turkey Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Saudi Arabia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. UAE Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2021-2032) Figure 58. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2021-2032) Figure 59. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (US$/Unit) by Type (2021-2032) Figure 60. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2021-2032) Figure 61. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2021-2032) Figure 62. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (US$/Unit) by Application (2021-2032) Figure 63. Glucagon-like Peptide-2 (GLP-2) Agonist Value Chain Figure 64. Glucagon-like Peptide-2 (GLP-2) Agonist Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Opportunities and Challenges

Scope & coverage.

Types
  • Gattex
  • Revestive
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Takeda Pharmaceuticals

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size (2021-2032)
  4. 2.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (2021-2032)
  5. 2.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Average Price (2021-2032)
  6. 2.3 Glucagon-like Peptide-2 (GLP-2) Agonist by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Gattex
  9. 2.3.3 Revestive
  10. 2.4 Glucagon-like Peptide-2 (GLP-2) Agonist by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital
  13. 2.4.3 Pharmacy
  14. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Glucagon-like Peptide-2 (GLP-2) Agonist Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Product Type & Application
  8. 3.8 Global Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, Established Date
  9. 3.9 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Takeda Pharmaceuticals
  2. 4.1.1 Takeda Pharmaceuticals Company Information
  3. 4.1.2 Takeda Pharmaceuticals Business Overview
  4. 4.1.3 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Portfolio
  6. 4.1.5 Takeda Pharmaceuticals Recent Developments
5 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Scenario by Region
  1. 5.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2021-2032
  3. 5.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2021-2026
  4. 5.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2027-2032
  5. 5.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region: 2021-2032
  6. 5.3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region: 2021-2026
  7. 5.3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region: 2027-2032
  8. 5.4 North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
  9. 5.4.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2032)
  11. 5.4.3 North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
  15. 5.5.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2032)
  17. 5.5.3 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
  35. 5.7.1 South America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2032)
  37. 5.7.3 South America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2032)
  2. 6.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2021-2032)
  4. 6.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021-2032)
  5. 6.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2032)
  2. 7.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2021-2032)
  4. 7.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021-2032)
  5. 7.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Glucagon-like Peptide-2 (GLP-2) Agonist Value Chain Analysis
  2. 8.1.1 Glucagon-like Peptide-2 (GLP-2) Agonist Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Glucagon-like Peptide-2 (GLP-2) Agonist Production Mode & Process
  5. 8.2 Glucagon-like Peptide-2 (GLP-2) Agonist Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Glucagon-like Peptide-2 (GLP-2) Agonist Distributors
  8. 8.2.3 Glucagon-like Peptide-2 (GLP-2) Agonist Customers
9 Global Glucagon-like Peptide-2 (GLP-2) Agonist Analyzing Market Dynamics
  1. 9.1 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Trends
  2. 9.2 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Drivers
  3. 9.3 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Opportunities and Challenges
  4. 9.4 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst